Harbour BioMed Included in Stock Connect Program

Harbour BioMed, a global biopharmaceutical company, has achieved a significant milestone by being included in the Stock Connect program, allowing qualified investors in mainland China to directly invest in its shares. This inclusion, effective immediately, reflects the company's strong market performance and growing recognition in the capital markets.

As of the first half of 2026, Harbour BioMed reported a total revenue of approximately US$122.5 million, marking a 20.9% increase year-over-year. The company's adjusted net profit reached US$71.6 million, confirming its normalized profitability and validating its business model. As of June 30, 2026, the company held cash and cash equivalents of approximately US$359.2 million, providing robust financial resources to support its strategic initiatives.

Harbour BioMed's pipeline includes nearly 30 differentiated drug candidates across various therapeutic areas, including immunology, oncology, metabolism, and the central nervous system. One of the company's lead assets, Batoclimab (HBM9161), has been submitted for Biologics License Application (BLA) review and is positioned as a potential blockbuster therapy for multiple autoimmune indications. Porustobart (HBM4003), a fully human heavy-chain-only antibody, has demonstrated positive efficacy and safety profiles in clinical trials targeting advanced solid tumors. HBM9378, a next-generation ultra-long-acting anti-TSLP monoclonal antibody, has achieved several key milestones, including the initiation of the Phase II SIRIUS study for the treatment of COPD by its subsidiary, Nona Biosciences.

The company has also made significant progress in innovative molecules such as HBM7575, HBM7020, and LET003, underscoring its capabilities in target selection and molecular design. Harbour BioMed has established itself as a leading force in biotech BD partnerships through its proprietary antibody technology platform, Harbour Mice®. The platform generates fully human monoclonal antibodies in both conventional and heavy chain-only formats, enabling the development of next-generation therapeutic antibodies.

Notable out-licensing transactions have propelled Harbour BioMed's core pipeline into the global market. For instance, the company has out-licensed ex-China rights for HBM9378 to Windward Bio, an ex-China licensing agreement for HBM7020 with Otsuka Pharmaceutical, a license agreement and equity partnership with Solstice Oncology for HBM4003, and a licensing and collaboration agreement with AstraZeneca for HBM7022. These partnerships have demonstrated the company's strategic execution capabilities and its ability to unlock the global value of its pipeline.

Harbour BioMed's commitment to innovation is further highlighted by its integration of AI into drug R&D. In October 2025, the company unveiled its first fully human AI HCAb generation and screening model, powered by the Hu-mAtrIx™ platform. This model accelerates the development of innovative therapies by providing a closed loop of "AI design, intelligent screening, wet-lab validation." LET003, a product of this initiative, has shown promising results.

The inclusion in the Stock Connect program is expected to expand Harbour BioMed's investor base and enhance its access to capital, supporting the company's ongoing research and development efforts. The company's robust financial position, diverse pipeline, and strategic partnerships position it well for continued growth and success in the biopharmaceutical industry. With this milestone, Harbour BioMed is poised to further strengthen its market position and contribute to the advancement of medical treatments.

The company’s inclusion in the Stock Connect program is a testament to its financial strength and the growing recognition of its contributions to the biopharmaceutical sector. As it continues to innovate and expand its global reach, Harbour BioMed is well-positioned to deliver on its mission of improving patient outcomes through advanced therapies.